Lewis Silverman, an oncologist with Mount Sinai Medical Center, discusses a clinical trial involving Revlimid (lenalidomide) for patients with a type of myelodysplastic syndrome.
Revlimid is currently approved for patients with a specific type of MDS that contains a chromosomal abnormality called deletion 5q.
The phase 3 trial,which was reported at the 2014 American Society of Hematology, includes patients with MDS who do not have the chromosomal abnormality but have low-risk disease.
The purpose of the study was to find out if Revlimid could reduce the number of red blood cell transfusions needed by anemic (transfusion-dependent) patients with low- or intermediate-risk MDS without a deletion 5q chromosome abnormality.
Silverman says the study confirms that about a quarter of patients who do not have the deletion 5q abnormality can become transfusion independent, and the duration of treatment response is about eight or nine months.
